MoonLake Immunotherapeutics AG

Address: Dorfstrasse 29

Sponsor Overview

assignment

Specializations

Hidradenitis suppurativa

Clinical research in hidradenitis suppurativa focuses on moderate-to-severe disease, with attention to both symptom control and longer-term safety and tolerability outcomes.

Inflammatory skin disease
Moderate-to-severe hidradenitis suppurativa
Long-term safety

Trials in this area reflect interest in persistent cutaneous inflammation and treatment response over extended follow-up.

Psoriatic arthritis

Research in psoriatic arthritis centers on active disease, with outcomes linked to improvement in joint inflammation, clinical response, and ongoing treatment tolerability.

Active psoriatic arthritis
Joint inflammation
Long-term efficacy

This therapeutic area also includes patients with prior treatment exposure and those with biologic-naive disease.

Palmoplantar pustulosis

Studies in palmoplantar pustulosis address localized pustular psoriasis affecting the palms and soles, with emphasis on improvement in disease severity and visible inflammatory burden.

Palmoplantar pustulosis
Pustular psoriasis
Skin severity assessment

Work in this field highlights interest in difficult-to-treat dermatologic inflammation.

Axial spondyloarthritis

Clinical activity in axial spondyloarthritis reflects interest in inflammatory disease of the spine and sacroiliac joints, including imaging-based assessment of active lesions and disease activity.

Axial spondyloarthritis
Inflammatory back disease
Imaging biomarkers

These studies connect musculoskeletal inflammation with molecular imaging approaches.

Immunology and inflammatory disease

The sponsor’s trial portfolio is concentrated in immune-mediated inflammatory disorders, spanning dermatology and rheumatology with shared mechanisms of chronic inflammation.

Immune-mediated disease
Dermatology
Rheumatology

Across these areas, the clinical focus includes inflammatory pathways, symptom burden, and sustained treatment effects.

Sponsored Trials

Trial Name	Country	Status
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis	Bulgaria Croatia Czechia Estonia Finland France Germany Greece Hungary Latvia Lithuania Poland Portugal Romania Slovakia Spain	Not Yet Recruiting
Efficacy and Safety Evaluation of Subcutaneous Sonelokimab in Adults with Moderate to Severe Hidradenitis Suppurativa: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study	Belgium Bulgaria Czechia France Germany Ireland Poland Slovakia Spain The Netherlands	Not Recruiting
Efficacy and Safety of Subcutaneous Sonelokimab Versus Placebo and Risankizumab in Adults with Active Psoriatic Arthritis and Inadequate Response to TNF-α Inhibitors	Bulgaria Czechia France Germany Hungary Poland Spain	Recruiting
Long-term Safety, Tolerability, and Efficacy Evaluation of Subcutaneous Sonelokimab in Moderate to Severe Hidradenitis Suppurativa	Belgium Bulgaria Czechia France Germany Hungary Italy Norway Poland Portugal Slovakia Spain The Netherlands	Not Recruiting
Phase 2 Multicenter Open-Label Study of Sonelokimab in Moderate-to-Severe Palmoplantar Pustulosis Patients	Germany	Not Recruiting
Phase 2 Open-Label Imaging Study of Sonelokimab in Active Psoriatic Arthritis and Axial Spondyloarthritis Using 68Ga-FAPI-46 PET/CT	Germany	Recruiting
Phase 2 Open-Label Imaging Study on Sonelokimab's Effects in Active Axial Spondyloarthritis Evaluated by 18NaF PET Scan Tracer Uptake	Germany	Not Recruiting
Phase 3 Randomized Double-Blind Study of Subcutaneous Sonelokimab in Biologic DMARD-Naive Adults with Active Psoriatic Arthritis	Bulgaria Croatia Czechia Estonia Finland France Germany Greece Hungary Latvia Lithuania Poland Portugal Romania Slovakia Spain	Not Recruiting
Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of Subcutaneous Sonelokimab in Adults with Moderate‑to‑Severe Hidradenitis Suppurativa	Austria Bulgaria Germany Hungary Italy Norway Poland Portugal	Not Recruiting